News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Investing.com Australia Earnings
This article reports that Ensysce Biosciences Inc. filed a Form 8K on August 13. The company's stock symbol is ENSC, which saw a 14.75% increase. The article provides only this financial filing information without further details on the content of the Form 8K.
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Ensysce Biosciences' President, James William Morrison, reported an indirect holding of 154,821 Series C Non-Voting Convertible Preferred Stock shares through Belgarion Ventures Ltd. These preferred shares are convertible into 154,821,000 common shares, contingent on stockholder approval and Nasdaq rules, with a beneficial ownership limitation. …
Ensysce Biosciences (NASDAQ: ENSC) has acquired Cy Biopharma Inc. and secured up to $77 million in financing, combining their pain management portfolios. This deal aims to advance a late-stage pipeline, including Cy Biopharma’s lead candidate CY200 for Complex Regional Pain Syndrome Type 1, which …
Ensysce Biosciences has acquired Cy Biopharma in a deal valued at up to $77 million, significantly broadening its focus beyond opioids into neuroplastogenic pain therapeutics. This acquisition transforms Ensysce into a more diverse pain management company, incorporating Cy Biopharma's clinical-stage neuroplastogenic program, CY200, for …
This article from Investing.com reports on Ensysce Biosciences Inc's Form 8K filing for August 6th. The filing is a standard requirement by the SEC for significant events that shareholders should know about. The brief article indicates that Ensysce Biosciences Inc. (ENSC) has seen a …
Ensysce Biosciences, Inc. (NASDAQ: ENSC) has completed its acquisition of Cy Biopharma, Inc., a clinical-stage biotech company focused on neuroplastogenic therapies for complex pain. This acquisition, which includes $17.1 million in cash from pre-acquisition financing, is accompanied by a private placement expected to generate …
Ensysce Biosciences has acquired Cy Biopharma, gaining CY200, a clinical-stage therapy with FDA Orphan Drug Designation for Complex Regional Pain Syndrome Type 1. The acquisition includes $17.1 million in cash from Cy Biopharma and a private placement expected to raise approximately $43 million in …
Ensysce Biosciences (ENSC) stock surged 52.6% in pre-open trading after the company announced a formal strategic review to explore partnerships, licensing deals, or asset sales. This move follows positive corporate developments, including a $5.3 million award from the National Institute on Drug Abuse and …
Ensysce Biosciences (NASDAQ:ENSC) saw its shares surge by 48% in premarket trading, but still needs a 141% increase to meet Nasdaq's $1 minimum bid price requirement. The company faces delisting concerns due to its low stock price and a deficit in stockholders' equity, and …
This article lists 12 healthcare stocks that experienced significant movement during Monday's after-market trading session. It details both gainers, such as Ensysce Biosciences and TransCode Therapeutics, and losers, including Addex Therapeutics and ClearPoint Neuro, providing their stock performance, current prices, and market capitalizations. The …
Ensysce Biosciences Inc (ENSC) has a weak financial status and low operating efficiency, ranking 260 out of 384 in the Biotechnology & Medical Research industry with a financial score of 6.34. The company's latest quarterly revenue decreased by 27.18% year-over-year to $961.00K, and its …
This article from TradingKey provides an overview of Ensysce Biosciences Inc (ENSC) stock data, including its current price, market cap, and P/E TTM. It highlights that detailed revenue breakdown by business segments and regions for ENSC has not yet been disclosed by the company. …
This article provides an "Institutional Confidence" score for Ensysce Biosciences Inc (ENSC) as part of TradingKey's stock analysis. The current score is 3.00 with no change from the previous score, and it lists key institutional shareholders along with their shareholdings and recent activity percentage …
This article provides details on the dividend and stock split history for Ensysce Biosciences Inc (ENSC). It notes that the company has distributed no dividends over the past five years. However, it lists several stock merger events, including a 15-for-1 merger scheduled for December …
This article details the shareholder structure of Ensysce Biosciences Inc (ENSC), outlining its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdings for key investors.
TradingKey provides a comprehensive stock analysis for Ensysce Biosciences Inc (ENSC), highlighting its strong fundamentals, high growth potential, and relatively fair valuation within the Biotechnology & Medical Research industry. Despite a recent weak stock market performance and institutional selling, analysts have a high price …
Jeffrey Millard, the Chief Operating Officer of Ensysce Biosciences, has resigned from his position, with the resignation becoming effective on July 10, 2026. The reasons for his departure and details about his replacement have not been disclosed. This information is based on an SEC …
Jeffrey Millard resigned from his position as Chief Operating Officer of Ensysce Biosciences (Nasdaq: ENSC), effective July 10, 2026. The company officially reported this material event via an 8-K filing on July 15, 2026. Ensysce Biosciences emphasizes its status as an emerging growth company, …
Ensysce Biosciences (NASDAQ: ENSC) has received a $5.3 million award from the National Institutes on Drug Abuse (NIDA) to advance its MPAR overdose-protection technology, specifically for its lead agent PF614-MPAR. This funding, part of a total $15.1 million support over three years, will facilitate …
Ensysce Biosciences has received the final $5.3 million installment of a $15.1 million federal grant from the National Institutes on Drug Abuse (NIDA). This funding will advance the development of PF614-MPAR, a novel opioid with oral overdose protection that has received FDA Breakthrough Therapy …
Ensysce Biosciences has received a $5.3 million installment from the National Institute on Drug Abuse (NIDA), completing a multi-year federal grant of approximately $15.1 million. This funding will support the continued nonclinical and clinical development of PF614-MPAR, a first-in-class opioid designed with MPAR overdose-protection …
Search by ticker symbol or company name and select a result to open its chart.